🎉 M&A multiples are live!
Check it out!

Daxor Valuation Multiples

Discover revenue and EBITDA valuation multiples for Daxor and other public comps.

See Daxor Valuation Multiples

Daxor Overview

About Daxor

Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.


Founded

1971

HQ

United States of America
Employees

12

Website

daxor.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$37.8M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Daxor Financials

Daxor has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Daxor achieved revenue of $1.3M and an EBITDA of n/a.

Daxor expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Daxor valuation multiples based on analyst estimates

Daxor P&L

FY 2022 FY 2023 FY 2024 LTM NTM
Revenue $6.3M $1.3M n/a n/a XXX
Gross Profit n/a n/a n/a XXX XXX
Gross Margin NaN% NaN% NaN% XXX XXX
EBITDA n/a n/a n/a n/a XXX
EBITDA Margin NaN% NaN% NaN% NaN% XXX
Net Profit $4.7M $5.2M $0.3M XXX XXX
Net Margin 75% 404% NaN% XXX XXX
Net Debt $3.0M $1.2M $0.8M XXX XXX

Financial data powered by Morningstar, Inc.

Daxor Stock Performance

As of February 7, 2025, Daxor's stock price is $7.

Daxor has current market cap of $36.1M, and EV of $37.8M.

See Daxor trading valuation data

Daxor Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$37.8M $36.1M XXX XXX XXX XXX n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Daxor Valuation Multiples

As of February 7, 2025, Daxor has market cap of $36.1M and EV of $37.8M.

Daxor's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Daxor's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Daxor and 10K+ public comps

Daxor Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $37.8M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA n/a XXX XXX XXX
P/E n/a XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Daxor Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Daxor Valuation Multiples

Daxor's NTM/LTM revenue growth is n/a

Daxor's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.1M for the same period.

Over next 12 months, Daxor's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Daxor's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Daxor and other 10K+ public comps

Daxor Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth n/a XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $0.1M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 24% XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue 78% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Medical Devices
Consumer SaaS
Streaming Platforms
AdTech Software
Climate Tech
GRC Software
Developer Tools

Daxor Public Comps

See valuation multiples for Daxor public comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Philips XXX XXX XXX XXX XXX XXX
Perspective Therapeutics XXX XXX XXX XXX XXX XXX
Electromed XXX XXX XXX XXX XXX XXX
InfuSystem XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Daxor M&A and Investment Activity

Daxor acquired  XXX companies to date.

Last acquisition by Daxor was  XXXXXXXX, XXXXX XXXXX XXXXXX . Daxor acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Daxor

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Daxor

When was Daxor founded? Daxor was founded in 1971.
Where is Daxor headquartered? Daxor is headquartered in United States of America.
How many employees does Daxor have? As of today, Daxor has 12 employees.
Who is the CEO of Daxor? Daxor's CEO is Mr. Michael R. Feldschuh.
Is Daxor publicy listed? Yes, Daxor is a public company listed on NAS.
What is the stock symbol of Daxor? Daxor trades under DXR ticker.
When did Daxor go public? Daxor went public in 1992.
Who are competitors of Daxor? Similar companies to Daxor include e.g. Philips, Perspective Therapeutics, Electromed, InfuSystem.
What is the current market cap of Daxor? Daxor's current market cap is $36.1M
Is Daxor profitable? Yes, Daxor is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.